Figure 5.

T-cell trafficking into HER2⁺ human breast cancer PDX in DKO mice to exert antitumor effect. A, Representative bioluminescence images of T-cell trafficking over days of BsAb treatment. B, Quantitation of T-cell trafficking into tumors over time by bioluminescence (n = 5 mice/group) expressed as total flux or radiance (photons/sec) in each pixel integrated over the entire tumor contour (ROI). C, Representative immunohistochemistry images of huCD45⁺ T-cell infiltration in tumor sections on day 6 (100X magnifications). D, Tumor response among HER2⁺ breast cancer PDX (M37) (n = 5 mice/group) after treatment with Ctrl-BsAb, Her2-BsAb and its Fc mutants. The results shown are representative results from at least three independent repeats. The significant differences were calculated based on AUC, shown in Supplementary Fig. S8.